40685-92-5

Usage

Uses

Used in Pharmaceutical Industry:
Hydrazinecarboxamide, N,N-dimethylis used as an intermediate in the synthesis of various pharmaceuticals. Its ability to act as a coupling agent allows for the creation of amide and sulfonamide derivatives, which are essential components in the development of new drugs.
Used in Agrochemical Industry:
hydrazinecarboxamide, N,N-dimethylis utilized in the production of herbicides, which are essential for controlling and preventing the growth of unwanted plants in agricultural fields, ensuring optimal crop yield and quality.
Used in Chemical Stabilization:
Hydrazinecarboxamide, N,N-dimethylserves as a stabilizer in organic peroxides, which are widely used in various industries, including plastics, rubber, and coatings. Its stabilizing properties help prevent the premature decomposition of these materials, ensuring their stability and performance.
Used in Water Treatment:
As a corrosion inhibitor, hydrazinecarboxamide, N,N-dimethylis used in water treatment processes to prevent the corrosion of metal surfaces in pipelines and storage tanks. This helps extend the life of the infrastructure and maintain water quality.

InChI:InChI=1/C3H9N3O/c1-6(2)3(7)5-4/h4H2,1-2H3,(H,5,7)

Upstream product

• 124-40-3 dimethyl amine 
• 687-48-9 ethyl N,N-dimethylcarbamate 
• 407-43-2 dimethyl-carbamic acid-(2,2,2-trifluoro-ethyl ester) 
• 79-44-7 N,N-Dimethylcarbamoyl chloride 

Downstream Products

• 104707-14-4 benzaldehyde 4,4-dimethyl-semicarbazone 
• 344442-67-7 1-(2-amino-5-chlorobenzoyl)-4,4-dimethylsemicarbazide 
• 93595-29-0 1-o-aminobenzoyl-4,4-dimethylsemicarbazide 
• 344442-66-6 1-(5-methyl-2-aminobenzoyl)-4,4-dimethylsemicarbazide 
• 93595-31-4 C₁₆H₁₈N₄O₂ 
• 5499-37-6 4-Chlor-benzaldehyd-<4,4-dimethyl-semicarbazon> 
• 25874-98-0 2-Chlor-benzaldehyd-(4,4-dimethyl-semicarbazon) 
• 93595-30-3 1-o-aminobenzoyl-4,4-dimethylsemicarbazide 
• 93595-32-5 C₁₇H₁₇F₃N₄O₂ 

Relevant academic research and scientific papers

New Biguanides as Anti-Diabetic Agents Part I: Synthesis and Evaluation of 1-Substituted Biguanide Derivatives as Anti-Diabetic Agents of Type II Diabetes Insulin Resistant

New 1-substituted-biguanide hydrochloride salts were synthesized via reacting benzo[1,3-d]dioxol-5-amine, phenylhydrazine, N,N-dimethylhydrazinecarboxamide, benzohydrazide and 2-phenyl acetohydrazide with dicyandiamide in acidic medium. Structures of the obtained biguanide salts were characterized by spectroscopic tools. The synthesized compounds were screened for their anti-diabetic activity with standard metformin drug. Oral treatment of hyperglycemic rats with the synthesized biguanide derivatives significantly decreased the elevated blood glucose level. Additionally, anti-diabetic properties towards liver function enzyme activities (AST, ALT and ALP), lipids profiles (TC, TG and TL), lipid peroxide and nitrous oxide as well as histopathological studies relative to metformin hydrochloride were investigated and discussed.

PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS

The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS

The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS

The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

Synthesis, properties, and application of 4-nitrosemicarbazones

The studies of the condensation of 4-nitrosemicarbazide (4-NSC) with various aldehydes and ketones resulted in the development of an approach to the synthesis of N-nitrosemicarbazones, promising high-energy and biologically active compounds. Subsequent treatment with amines and alkalis led to the synthesis of water-soluble salts of nitrosemicarbazones, as well as the corresponding semicarbazones. The reaction of N,N′-diisopropyl- or N,N′-di-tert-butyl-1,2-ethanediimine with 4-nitrosemicarbazide led to the synthesis of glyoxal bis(nitrosemicarbazone) derivatives. A computer-aided screening using the PASS software showed a probability of high biological activity for the compounds obtained, whereas antiarrhythmic properties of camphor nitrosemicarbazone potassium salt were confirmed in experiments in rats.

Facile one-pot synthesis of 4-substituted semicarbazides

A diverse library of twenty-five 4-mono- and disubstituted semicarbazides was prepared in a one-pot two-step approach. The method includes formation of a carbamate from bis(2,2,2-trifluoroethyl)carbonate or 2,2,2-trifluoroethylchloroformate and a primary or secondary amine and subsequent interaction of the carbamate with hydrazine to result in a semicarbazide. The approach allowed to obtain 4-substituted semicarbazides on a large scale in good yield and high purity. This journal is

Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors?

Starting from potent aldehyde inhibitors with poor drug properties, derivatization to semicarbazones led to the identification of a series of semicarbazone-based cathepsin K inhibitors with greater solubility and better pharmacokinetic profiles than their parent aldehydes. Furthermore, a representative semicarbazone inhibitor attenuated bone resorption in an ex vivo rat calvarial bone resorption model. However, based on enzyme inhibition comparisons at neutral pH, semicarbazone hydrolysis rates, and 13C NMR experiments, these semicarbazones probably function as prodrugs of aldehydes.

Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof

This invention is related to carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones represented by Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein: Y is oxygen or sulfur; R1, R21, R22 and R23 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl; or R22 and R23, together with the N, form a heterocycle; A1 and A2 are independently aryl, heteroaryl, saturated or partially unsaturated carbocycle or saturated or partially unsaturated heterocycle, any of which is optionally substituted; X is one or O, S, NR24, CR25R26, C(O), NR24C(O), C(O)NR24, SO, SO2 or a covalent bond; where R24, R25 and R26 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl. The invention also is directed to the use of carbocycle and heterocycle substituted semicarbazones and thiosemicarbazones for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), for the treatment and prevention of otoneurotoxicity and eye diseases involving glutamate toxicity and for the treatment, prevention or amelioration of pain, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy and urinary incontinence.